


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”) announces that Mr. Tse, Eric S Y (“**Mr. Tse**”) has been appointed as an executive director and a member of the Executive Board Committee of the Company, with effect from 23 October 2019.

The biographical details of Mr. Tse are set out below:

Mr. Tse, Eric S Y, aged 24, holds a Bachelor of Science degree in Economics from the Wharton School of the University of Pennsylvania and a master degree in Management and Global Leadership from Schwarzman College, Tsinghua University. Mr. Tse joined the Company in June 2018 as an assistant to the president of the Company. Before joining the Company, Mr. Tse served as the chief executive officer of Liepin North America, a reputable human resources company, where he was responsible for the overall overseas business of Liepin (獵聘網). During his one year service as the chief executive officer of Liepin North America, under the leadership of Mr. Tse, Liepin North America achieved exponential growth in sales and the number of Chinese students covered also increased significantly.

During his time at university, Mr. Tse founded the Penn Wharton China Summit and has developed the summit to one of the most influential folk ties between China and overseas elites in America. The summit held its fifth session in this year. At the end of 2016, he established the China Summit Foundation, which is dedicated to promoting cultural, public welfare, education, forums and other projects initiated by overseas students. He also served as the head of external affairs of the Wharton China Association and a core member of the Wharton Investment and Trading Group, demonstrating outstanding leadership and coordination skills. In 2018, he was appointed as an Asia-Pacific Economic Cooperation (APEC) Voices of the Future China Youth Representative and invited to participate in the APEC Summit together with the leaders in political and business. Mr. Tse was awarded the “Top Ten

Outstanding Chinese American Youth” in 2018 (the list of which was jointly selected by the All America Chinese Youth Federation, the American Chinese Public Diplomacy Association, and the English “Los Angeles Post”).

Save as disclosed above, Mr. Tse (i) does not hold any other position in the Company or any of its subsidiaries; and (ii) did not hold any directorship in other listed companies in the three years immediately before the date of this announcement. He is the son of Mr. Tse Ping and Ms. Cheng Cheung Ling, both being executive directors and substantial shareholders of the Company, the brother of Miss Tse, Theresa Y Y, the Chairlady of the Board and a substantial shareholder of the Company, and a nephew of each of Mr. Tse Hsin, an executive director of the Company, Ms. Chia Fai, Miss Tse Wun, and Mr. Tse Hsuan, Johnny, all being senior management of the Company. Other than that, he does not have any relationship with any directors, senior management, and substantial or controlling shareholders of the Company.

There is no service contract entered into between the Company and Mr. Tse. He has not been appointed for a specific term but shall be subject to retirement by rotation and re-election at annual general meeting in accordance with the Company’s Articles of Association. Mr. Tse is entitled to receive a remuneration of HK\$3.9 million per annum and discretionary bonuses, which are determined with reference to his anticipated time and effort to be exercised on the Company’s matter and the remuneration benchmarks in the industry.

As at the date of this announcement, Mr. Tse holds in aggregate 2,700,000,000 shares of the Company through his interests in Thousand Eagles Limited and Remarkable Industries Limited. Other than that, Mr. Tse does not have any interest or short position in shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Tse has confirmed that, there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and there is no other matter relating to his appointment that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to extend its warmest welcome to Mr. Tse for joining the Board and will offer full support to his appointment. The Board hopes that Mr. Tse would bring more creativity and vitality to the Board.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairlady

Hong Kong, 23 October 2019

As at the date of this announcement, the Board of the Company comprises eight Executive Directors, namely Miss Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.